Therakind collaborates with Indosys to develop a novel dry powder nasal device
Development of a new drug delivery platform
Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces it has reached an exclusive licensing agreement with Indosys Limited for the development of an innovative dry powder nasal device.
Intranasal medicine delivery not only allows for accurate and consistent dose delivery that achieves rapid, effective blood levels of the administered medication. It also allows for non-invasive, needle-free and painless administration which is suitable for the delivery of small molecules, proteins and peptides. The new device will form the basis of novel delivery platform to be developed exclusively by Therakind.
Susan Conroy, CEO of Therakind, said:
“We are excited to collaborating with Indosys to develop a new delivery system that will enable pain-free delivery of medications, both our own and for future partners. This partnership reflects our passion to work with specialists to design and distribute safe and innovative medicines and delivery devices to improve care through better treatment regimens for patients.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche products in difficult-to-treat markets including paediatric and geriatric patient groups. We have three paediatric products on the market, with Jylamvo, our European approved oral methotrexate for treating rheumatological and dermatological diseases expanded to treat adults, and DriDose®, our Dry Powder Intranasal Device for the delivery of a dry powder drug formulation available for partnering. Our proprietary pipeline is focused on improving medicine adherence through easier dosing regimens and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
To find out more, please head to www.therakind.com
